CR845-310302: A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus
Public ClinicalTrials.gov record NCT05356403. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-blind, Placebo-controlled 12-Week Study to Evaluate the Safety and Efficacy of Oral Difelikefalin in Advanced Chronic Kidney Disease Subjects With Moderate-to-Severe Pruritus With an up to 52-Week Long-term Extension
Study identification
- NCT ID
- NCT05356403
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Cara Therapeutics, Inc.
- Industry
- Enrollment
- 105 participants
Conditions and interventions
Conditions
Interventions
- Difelikefalin 1 mg Oral Tablet Drug
- Placebo Oral Tablet Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 25, 2022
- Primary completion
- Feb 25, 2024
- Completion
- Feb 25, 2024
- Last update posted
- May 6, 2024
2022 – 2024
United States locations
- U.S. sites
- 9
- U.S. states
- 6
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Cara Therapeutics Study Site | Northridge | California | 91324 | — |
| Cara Therapeutics Study Site | Miami | Florida | 33032 | — |
| Cara Therapeutics Study Site | Miami Lakes | Florida | 33014 | — |
| Cara Therapeutics Study Site | Miami Lakes | Florida | 33016 | — |
| Cara Therapeutics Study Site | Weston | Florida | 33331 | — |
| Cara Therapeutics Study Site | Brunswick | Georgia | 31520 | — |
| Cara Therapeutics Study Site | New York | New York | 10016 | — |
| Cara Therapeutics Study Site | Orangeburg | South Carolina | 29118 | — |
| Cara Therapeutics Study Site | Sugar Land | Texas | 77476 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 66 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05356403, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 6, 2024 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05356403 live on ClinicalTrials.gov.